• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute.

作者信息

Rule S, Briones J, Smith R, Theodore Oklota C, Ngoh C A, Osborne S, Capochiani E, Rummel M

机构信息

Derriford Hospital, Plymouth, UK.

Santa Creu i Sant Pau Hospital, Barcelona, Spain.

出版信息

Value Health. 2014 Nov;17(7):A537. doi: 10.1016/j.jval.2014.08.1719. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.1719
PMID:27201719
Abstract
摘要

相似文献

1
Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute.在完成随机III期研究Prefmab和Mabcute中Rasq测量的CD20+非霍奇金淋巴瘤（NHL）患者中对利妥昔单抗皮下（Sc）和静脉内（Iv）给药的偏好
Value Health. 2014 Nov;17(7):A537. doi: 10.1016/j.jval.2014.08.1719. Epub 2014 Oct 26.
2
Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab.非霍奇金淋巴瘤治疗满意度问卷的验证：评估利妥昔单抗从静脉给药改为皮下给药后的变化
Patient Prefer Adherence. 2016 Sep 13;10:1767-1776. doi: 10.2147/PPA.S108489. eCollection 2016.
3
The therapeutic use of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的治疗应用。
Eur J Haematol Suppl. 2007 Jan(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.
4
The cost-effectiveness of rituximab in non-Hodgkin's lymphoma.利妥昔单抗在非霍奇金淋巴瘤中的成本效益。
Expert Rev Pharmacoecon Outcomes Res. 2007 Aug;7(4):319-26. doi: 10.1586/14737167.7.4.319.
5
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.维妥珠单抗，一种用于治疗非霍奇金淋巴瘤、慢性淋巴细胞白血病和免疫性血小板减少性紫癜的抗CD20单克隆抗体。
Curr Opin Mol Ther. 2009 Apr;11(2):200-7.
6
A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.利妥昔单抗十年：改善非霍奇金淋巴瘤的生存结局
Annu Rev Med. 2008;59:237-50. doi: 10.1146/annurev.med.59.060906.220345.
7
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.初诊小儿成熟 B 细胞非霍奇金淋巴瘤和伯基特白血病中利妥昔单抗的 II 期窗研究。
J Clin Oncol. 2010 Jul 1;28(19):3115-21. doi: 10.1200/JCO.2009.26.6791. Epub 2010 Jun 1.
8
Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.组蛋白去乙酰化酶抑制剂与利妥昔单抗联合作用对非霍奇金B淋巴瘤细胞凋亡的影响
Exp Hematol. 2007 Dec;35(12):1801-11. doi: 10.1016/j.exphem.2007.06.009. Epub 2007 Aug 3.
9
Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.利妥昔单抗治疗非霍奇金淋巴瘤——随机对照试验的批判性评价。
Expert Opin Biol Ther. 2013 May;13(5):803-11. doi: 10.1517/14712598.2013.786698.
10
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.利妥昔单抗（美罗华，抗CD20单克隆抗体）在非霍奇金淋巴瘤中调节的细胞和分子信号转导途径：对化疗增敏和治疗干预的影响。
Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349.

引用本文的文献

1
Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria.罕见阵发性夜间血红蛋白尿症治疗管理满意度问卷（TASQ）的概念验证
J Patient Rep Outcomes. 2021 Jun 21;5(1):45. doi: 10.1186/s41687-021-00319-9.
2
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.在复发或难治性惰性非霍奇金淋巴瘤患者中进行皮下利妥昔单抗延长维持治疗的疗效和安全性评估：III 期 MabCute 研究的结果。
Haematologica. 2022 Feb 1;107(2):500-509. doi: 10.3324/haematol.2020.274803.
3
Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements.
皮下注射给予大剂量/大容量生物制剂：现状与未来进展展望。
Drug Des Devel Ther. 2021 Jan 13;15:159-170. doi: 10.2147/DDDT.S287323. eCollection 2021.
4
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.一项由加拿大癌症临床试验组进行的 durvalumab（抗 PD-L1）联合 tremelimumab（抗 CTLA-4）的 I 期临床试验，在晚期不可治愈的实体恶性肿瘤患者中同时或序贯给药。
Invest New Drugs. 2020 Oct;38(5):1442-1447. doi: 10.1007/s10637-020-00904-7. Epub 2020 Feb 4.
5
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.皮下注射利妥昔单抗治疗B细胞血液系统恶性肿瘤：科学依据与临床进展综述
Adv Ther. 2017 Oct;34(10):2210-2231. doi: 10.1007/s12325-017-0610-z. Epub 2017 Oct 5.
6
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.皮下和静脉注射利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松在一线弥漫性大 B 细胞淋巴瘤中的疗效和安全性：随机 MabEase 研究。
Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21.
7
A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.加拿大对利妥昔单抗皮下注射治疗非霍奇金淋巴瘤的观点。
Curr Oncol. 2017 Feb;24(1):33-39. doi: 10.3747/co.24.3470. Epub 2017 Feb 27.
8
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma.利妥昔单抗用于晚期滤泡性淋巴瘤维持治疗的批判性评价
Cancer Manag Res. 2015 Oct 27;7:319-30. doi: 10.2147/CMAR.S69145. eCollection 2015.